New Zealand s FY----/-- budget released in May ---- allocated NZD--.-bn (USD--.-mn) ...Measures announced together with the budget include plans to roll out a bowel cancer screening programme and additional funds to provide access to new treatments. Starting from July - ----, the Pharmaceutical Management Agency will use the Factors for Consideration to replace the Decision Criteria. ...In August ----, New Zealand s Pharmaceutical Management Agency announced that it will be funding Keytruda (pembrolizumab) starting from September ----. According to the agency s operations director, Sarah Fitt, new information has emerged that gives them the confidence to proceed with the funding decision.
...BMI View: New Zealand s Pharmaceutical Management Agency (PHARMAC) will continue to leverage its dominant position as a central procurer of drugs in the country to drive cost savings. While the high standards used by the agency in its funding decisions will make the process difficult, PHARMAC does acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). ...BMI View: New Zealand s Pharmaceutical Management Agency (PHARMAC) will continue to leverage its dominant position as a central procurer of drugs in the country to drive cost savings. While the high standards used by the agency in its funding decisions will make the process difficult, PHARMAC does acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). This accentuates the need for multinational drugmakers operating in New Zealand to ensure that their treatments substantially improve healthcare outcomes. ...While the high standards used by the agency in its funding decisions will make the process difficult, PHARMAC does acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). This accentuates the need for multinational drugmakers operating in New Zealand to ensure that their treatments substantially improve healthcare outcomes.
...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...
...Commodification of generic drug sector will attract manufacturers from low-cost bases. The Trans-pacific partnership (TPP), once entered into force, is likely to reduce regulatory barriers and speed up the approval of high value pharmaceuticals and biologics for sale TPP also likely to restrain PHARMAC s ability to hold down prices Authorities commitment to tackling public health issues, such as the rising prevalence of infectious diseases. ...